3Groszmann RJ, Wongcharatrawee S. The hepatic venous pres- sure gradient: Anything worth doing should be done right [J]. Hepatology, 2004, 39(2):280-283. 被引量：1
4de Franchis R. Evolving consensus in portal hypertension. Rev port of the Baveno IV consensus workshop on methology of diag- nosis and therapy in portal hypertension[J]. J Hepatol, 2005, 43 (1): 167-176. 被引量：1
5Ge PS, Runyon BA. The changing role of beta-blocker therapy in patients with cirrhosis[J]. J Hepatol 2014,60(3):643-653. 被引量：1
6Vlachogiannakos J, Kougioumtzian A, Triantos C, et al. The ef- fect of somatostatin vs. octreotide in preventing post-endoscopic increase in hepatic venous pressure gradient in cirrhosis with bleeding varices [J]. Aliment Pharmacol Ther, 2007, 26(11-12): 1479-1487. 被引量：1
7Guadalupe GT, Arun JS, Norman DG, et al. Prevention and man- agement of gastroesophageal varices and variceal hemorrhage in cirrhosis [ J]. Hepatology, 2007, 46(3): 922-938. 被引量：1
8Guadalupe GT, Joseph L, and Members of the Veterans Affairs Hepatitis C Resource Center Program. Management and treat- ment of patients with cirrhosis and portal hypertension: recom- mendations from the department of veterans affairs hepatitis C resource center program and the national hepatitis C program [ J ]. Am J Gastroenterol, 2009, 10g (7): 1802-1829. 被引量：1
9Tsochatzis EA, Bosch J, Burroughs AK. New therapeutic para- digm for patients with cirrhosis [J]. Hepatology, 2012, 56(5): 1883-1992. 被引量：1
10Simonetto DA, Shah VH, Kamath PS. Primary prophylaxis of variceal bleeding [J ]. Clin Liver Dis ,2014,18(2):335-345. 被引量：1
